Entresto's Theoretical Alzheimer's Risk Draws Practical FDA Response
Executive Summary
FDA's authority to require post-marketing studies can extend to theoretical risks, even in absence of clinical evidence, office director Unger concluded when he overrode review team's more informal consensus with Novartis about how to address hypothetical risk of Alzheimer's from the heart failure drug; see our November Drug Review Profile.
You may also be interested in...
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.
Minimal Residual Disease Inches Closer To Supporting Myeloma Accelerated Approvals
US FDA’s oncology advisory committee will discuss two meta-analyses supporting use of MRD as a surrogate endpoint to support accelerated approval in multiple myeloma trials.